Research Article

Efficacy of the Low Dose Apatinib plus Chemotherapy on Advanced Gastric Carcinoma

Shen Gao,1 Xuan Li,2 Weigang Shi,2 Limin Huo,2 and Huimin Liu3

1Department of General Surgery, Handan First Hospital, Handan, Hebei Province, China
2Handan First Hospital, Handan, Hebei Province, China
3Affiliated Hospital of Hebei Engineering University, Handan, Hebei Province, China

Correspondence should be addressed to Limin Huo; huobxv28395@163.com and Huimin Liu; lehuijuwen566422@163.com

Received 23 November 2021; Revised 14 January 2022; Accepted 10 February 2022; Published 30 March 2022

Objective. To evaluate the efficacy of low dose apatinib plus chemotherapy on advanced gastric carcinoma. Methods. Eligible 50 patients with advanced gastric carcinoma admitted to the hospital from January 2019 to March 2020 were enrolled, and they were assigned into the control group (n = 25, chemotherapy) and observation group (apatinib plus chemotherapy). Changes of CEA, CA72-4, and VEGF levels were measured, and the efficacy of the two groups was evaluated by referring to KPS and RECIST. Results. Significant reduction was observed in CEA, CA72-4, and VEGF in both groups, and the treatment in the observation group resulted in a greater reduction (all $P < 0.05$). The observation group obtained significantly higher KPS scores of compared with the control group ($P < 0.05$). In addition, the treatment in the observation group led to a better control rate in relative to the control group according to RECIST the score ($P < 0.05$). Conclusion. The combination of low dose apatinib and chemotherapy might be a promising option for advanced gastric cancer and it merits clinical application.

1. Introduction

As one of the top five major malignant tumors worldwide, gastric cancer exhibits a high incidence and fatality rate, and threatens human health [1–3]. Currently, the mainstays for gastric cancer include conventional chemotherapy, radiotherapy, and surgery. However, for some advanced patients, the results of these methods are not satisfying [4–6]. With this background, massive studies about apatinib combined with chemotherapy are ongoing. Apatinib alone as second-line or followed therapy in treating metastatic adenocarcinoma gastric cancer showed improved progression-free survival (PFS) and overall survival. Preclinical and clinical studies indicated that antiangiogenic therapy improved the efficacy of immune checkpoint inhibitors. Apatinib selectively inhibits vascular endothelial growth factor (VEGF) receptor (VEGFR) 2 and showed activity in advanced cancer in retrospective reports [7–9]. Nevertheless, no study has yet specifically determined the efficacy of chemotherapy and apatinib in advanced gastric cancers. To fill the gap, we intended to evaluate its therapeutic effect aiming to provide a certain reference for clinical application.

2. Methods

2.1. Study Design and Participants. Between January 2019 and March 2020, 50 patients with advanced gastric cancer treated in our hospital were enrolled and were divided into two groups. The baseline data were well balanced with respect to the age, weight, clinical stage, and CEA, CA72-4, and VEGF levels between the two groups before enrollment, as shown in Table 1. The protocol was approved by the ethics committee of Affiliated Hospital of Hebei Engineering University (No. HBEUAH3987). All subjects gave written informed consent in accordance with the Declaration of Helsinki.

2.2. Inclusion and Exclusion Criteria. Inclusion criteria were as follows: (1) patients confirmed to be gastric cancer disease judgment, (2) patients who have failed in general treatment,
Table 1: Comparison of general data.

| Groups        | Age (years) | Body weight | Male/female | Clinical staging | Stage IV |
|---------------|-------------|-------------|-------------|------------------|----------|
| Control group | 57.20 ± 2.10| 62.19 ± 4.70| 3 : 2       | 9                | 16       |
| Observation group | 56.90 ± 2.30| 62.30 ± 4.60| 3 : 2       | 7                | 18       |

\[ \frac{t}{X^2} \]

\[
P > 0.05 \\
P > 0.05
\]

2.3. Treatment Methods. Control group: patients received FOLFOX4 regimen and chemotherapy for two weeks. (1) oxaliplatin (Shenzhen Neptunus Drug manufacturing company, SFDA approval No. H20031048, 85 mg/m²) was intravenously administered for 2 h, on day 1; (2) calcium folinate (Henan Furen Huaqingtang Pharmaceutical enterprise, SFDA approval No. H20084204, 200 mg/m²) was intravenously administered for 2 h, on day 1; (3) 5-fluorouracil (Hainan Sinochem United Pharmaceutical Industry Co., Ltd., SFDA approval number H20051626, 400 mg/m²) was intravenously administered on day 1; and (4) 5-fluorouracil (600 mg/m²) was intravenously administered for 22 h, on day 1 and day 2.

Observation group: patients received 500 mg of apatinib (Jiangsu Hengrui Pharmaceutical enterprise, SFDA approval No. H20140105) orally every day on the basis of chemotherapy regimen in the control group [10].

2.4. Outcome Measures. Tumor markers include carcinoembryonic antigen (CEA), CA72-4, and vascular epidermal growth factor (VEGF). Serum free VEGF was measured by ELISA, the kit was produced by Chemicon Company in the United States, and the operation was carried out according to the instructions. Roche 2010 electrochemiluminescence instrument was used to determine CEA and CA724, and the instrument supporting reagents were used.

The effectiveness was assessed by referring to Response Evaluation Criteria In Solid Tumors (RECIST). Complete response (CR) was as follows: disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to <10 mm. Partial response (PR) was as follows: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive disease (PD) was as follows: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm (note: the appearance of one or more new lesions is also considered progression). Stable disease (SD) was as follows: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

The physical health was evaluated using Karnofsky performance status (KPS). The KPS scale ranges from 100, which implies full functional capability to carry out normal daily activities without clinical evidence (symptoms or signs) of disease, to zero, which implies death. Significant intervening scores include 70 (cares for self (toileting, feeding, bathing, and dressing), but unable to carry out normal activity or do active work such as housekeeping, school activities, and driving a car), 50 (requires considerable assistance and frequent medical care), 40 (disabled: requires special care and assistance, in bed more than 50% of time), 30 (severely disabled: hospitalization necessary; active supportive treatment necessary, almost always in bed), 20 (very sick: hospitalization necessary and requires extensive nursing care by professionals and (or family)), and 10 (moribund, fatal processes progressing rapidly).

2.5. Statistical Analysis. All data analysis was performed with SPSS 20.0. Count data and measurement data were verified via \( \chi^2 \) and \( t \)-test and presented in the form of cases (percentage) and (mean ± standard deviation). All data were tested at a significance level of .05 (2-sided).

3. Results

3.1. Comparison of CEA, CA72-4, and VEGF. Significant reduction was observed in CEA, CA72-4, and VEGF in both groups, and the treatment in the observation group resulted in a greater reduction (all \( P < 0.05 \), Figures 1–3).

3.2. Comparison of KPS Scores. The observation group obtained significantly higher KPS scores of compared with the control group (\( P < 0.05 \), Figure 4).

3.3. Comparison of Treatment Effects. The treatment in the observation group led to a better control rate in relative to the control group according to RECIST the score (\( P < 0.05 \), Table 2).

4. Conclusion

At present, the treatment of advanced gastric cancer mostly uses second-line chemotherapy to inhibit the patient’s lesions [10, 11]. However, studies have shown that although chemotherapy can prolong the life cycle of patients to a certain extent, it is still difficult to achieve the expected therapeutic effect [12, 13]. Therefore, a combination of targeted
that there is a significant difference in CA72-4 levels between all groups of patients before and after treatment. Note: CA72-4: carcinoembryonic antigen; X: before and after treatment; Y: CA72-4 levels of the two groups of patients. The CA72-4 expression levels of all groups of patients before and after treatment were (6.37 ± 0.35 ng/mL) and (3.25 ± 0.39 ng/mL), while the CA72-4 levels of patients of the observation group were (6.37 ± 0.35 ng/mL) and (3.25 ± 0.39 ng/mL) before and after treatment. * and ** indicate a significant difference in CA72-4 expression levels of all groups of patients before and after treatment; control group: t = 16.17, P < 0.01; observation group: t = 28.40, P < 0.01. *** indicates that there is a significant difference in CA72-4 levels between all patients after treatment (t = 17.14, P < 0.01).

Figure 2: CA72-4 expression levels of all groups of patients between treatment. Note: CA72-4: cancer antigen 72-4; X: before and after treatment; Y: CA72-4 levels of the two groups of patients. The levels of CA72-4 in the control group between treatment were (7.07 ± 0.53 U/mL) and (5.96 ± 0.49 U/mL), while the levels of CA72-4 in the observation group before and after treatment were (7.13 ± 0.94 U/mL) and (2.52 ± 0.31 U/mL). * and ** indicate a significant difference in levels of CA72-4 between all groups of patients before and after treatment (control group: t = 7.69, P < 0.01; observation group: t = 23.29, P < 0.01). *** indicates that there is a difference in levels of CA72-4 between all groups after treatment (t = 29.66, P < 0.01).

Figure 3: VEGF expression levels of all groups of patients between treatment. Note: VEGF: vascular epidermal growth factor; X: before and after treatment; Y: the expression level of VEGF before and after treatment in the two groups. The VEGF levels of patients in control group between treatment were (395.3 ± 51.12 ng/L) and (297 ± 60.03 ng/L), while the VEGF levels of patients of observation group were (363.3 ± 52.34 ng/L) and (191 ± 56.31 ng/L). * and ** indicate a significant difference in VEGF levels between all patients between treatment (control group: t = 3.95, P < 0.01; observation group: t = 10.91, P < 0.01). *** indicates that there is a significant difference in VEGF levels between all groups of patients after treatment (t = 6.44, P < 0.01).

Figure 1: CEA expression levels of the two groups of patients before and after treatment. Note: CEA: carcinoembryonic antigen; X: before and after treatment; Y: CEA levels of the two groups of patients. The CEA levels of patients in control group between treatment were (5.51 ± 0.33 ng/mL) and (4.37 ± 0.33 ng/mL), while the CEA levels of patients of the observation group were (6.37 ± 0.35 ng/mL) before and after treatment. * and ** indicate a significant difference of CEA between all patients before and after treatment (control group: t = 17.94 U/mL, P < 0.01; observation group: t = 28.40, P < 0.01). *** indicates that there is a significant difference in CEA levels between all patients after treatment (t = 17.14, P < 0.01).

drugs and chemotherapy is often used to intervene in patients’ lesions in clinical practice. In this study, we analyzed the clinical application value of combination therapy by comparing the efficacy of monotherapy and apatinib in combination with chemotherapy.

In this study, compared with receiving a single chemotherapy intervention, patients receiving apatinib targeted therapy on this basis exhibited a marked lower level of certain tumor markers. Apatinib is a new type of small molecule targeting protein that can effectively inhibit the formation of blood vessels around cancer tissues, thereby effectively inhibiting the invasion and migration of gastric cancer cells [14]. A previous study pointed out that the level of VEGF in the patient’s serum is significantly correlated with the clinical stage of the tumor [15]. According to our results, the serum VEGF level of patients decreased significantly after treatment in patients who suffer from advanced gastric cancer. VEGFR facilitates the proliferation of vascular endothelial cells by activating the MAPK signaling pathway. The malignant expansion of tumors usually requires a lot of energy. As its scale continues to expand, cancer cells need to secrete growth factors such as VEGF, EGF, and ECF to promote the formation of blood vessels around them, thereby increasing the efficiency of nutrient transport [16]. The formation of blood vessels around the tumor is not only conducive to its own proliferation, but also provides favorable conditions for its metastasis and spread [17]. CEA and CA72-4 are also important factors that reflect the condition of cancer patients clinically. In this study, compared with
single chemotherapy, the levels of CEA and CA72-4 witnessed a significantly more reduction after receiving apatinib treatment. All these might be attributed to the fact that apatinib, as an oral small molecule TKI against angiogenesis, can block VEGFR-2 in advanced GCA patients and reduce the activation of mitogen-activated protein kinase, thus inhibiting the proliferation of vascular endothelial cells. Preliminary studies reported a promising result of apatinib monotherapy for gastric cancer, certain limitations merit attention. The small sample size should be stated as a major limitation of this study. It is suggested that future trials be planned with larger sample size to further verify the efficacy and safety of therapy.

Data Availability

The datasets used during the present study are available from the corresponding authors upon reasonable request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] L. Peng, K. Yu, Y. Li, and W. Xiao, “Gastric metastasis of recurrent hepatocellular carcinoma: a case report and literature review,” Journal of Cancer Research and Therapeutics, vol. 14, no. 12, pp. 1230–1232, 2018.
[2] K. Kai, M. Satake, and O. Tokunaga, “Gastric adenocarcinoma of fundic gland type with signet-ring cell carcinoma component: a case report and review of the literature,” World Journal of Gastroenterology, vol. 24, no. 26, pp. 2915–2920, 2018.
[3] L. Marano, F. Rondelli, A. Bartoli, M. Testini, G. Castagnoli, and G. Ceccarelli, “Oncologic Effectiveness and safety of spleenecomy in total gastrectomy for proximal gastric carcinoma: meta-analysis of randomized controlled trials,” Anticancer Research, vol. 38, no. 6, pp. 3609–3617, 2018.
[4] T. Shi, X. Song, Q. Liu et al., “Survival benefit of palliative gastrectomy followed by chemotherapy in stage IV gastric signet ring cell carcinoma patients: a large population-based study,” Cancer Medicine, vol. 8, no. 13, pp. 6010–6020, 2019.
[5] W. O. Lane, D. P. Nussbaum, Z. Sun, and D. G. Blazer, “Preoperative radiation therapy in the surgical management of gastric and junctional adenocarcinoma: should lymph node retrieval guidelines be altered?,” Journal of Gastrointestinal Oncology, vol. 117, no. 8, pp. 1708–1715, 2018.
[6] Q. Wang and D. Zhu, “The prognostic value of systemic immune-inflammation index (SII) in patients after radical operation for carcinoma of stomach in gastric cancer,” Journal of Gastrointestinal Oncology, vol. 10, no. 5, pp. 965–978, 2019.
[7] S. Salehi, A. H. Jafarian, M. Montazer, M. Moghbeli, and M. M. ForghaniFarid, “BRUCE protein, new marker for targeted therapy of gastric carcinoma,” Journal of Gastrointestinal Cancer, vol. 48, no. 2, pp. 151–155, 2017.
[8] Z. Liu, W. Ou, N. Li, and S. Y. Wang, “Apatinib monotherapy for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy,” Thoracic Cancer, vol. 9, no. 10, pp. 1285–1290, 2018.
[9] F. Teng, Z. Xu, J. Chen et al., “DUSP1 induces apatinib resistance by activating the MAPK pathway in gastric cancer,” Oncology Reports, vol. 40, no. 3, pp. 1203–1222, 2018.

[10] J. Li, S. Qin, J. Xu et al., “Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial,” Journal of Clinical Oncology, vol. 31, pp. 3219–3225, 2013.

[11] S. Yang, X. L. Liu, X. L. Guo et al., “Solitary metastasis to the skin and colon from gastric cancer after curative gastrectomy and chemotherapy: a case report,” Medicine, vol. 99, no. 31, article e21532, 2020.

[12] Y. Li, F. H. Ma, L. Y. Xue, and Y. T. Tian, “Neoadjuvant chemotherapy vs upfront surgery for gastric signet ring cell carcinoma: a retrospective, propensity score-matched study,” World Journal of Gastroenterology, vol. 26, no. 8, pp. 818–827, 2020.

[13] D. Mei, B. Zhao, J. Zhang et al., “Impact of lymphovascular invasion on survival outcome in patients with gastric cancer,” American Journal of Clinical Pathology, vol. 153, no. 6, pp. 833–841, 2020.

[14] M. Morita, K. Taguchi, M. Kagawa et al., “Treatment strategies for neuroendocrine carcinoma of the upper digestive tract,” International Journal of Clinical Oncology, vol. 25, no. 5, pp. 842–850, 2020.

[15] N. Wang, S. Chen, D. Liu et al., “Therapeutic effect of small molecule targeting drug apatinib on gastric cancer and its role in prognosis and anti-infection mechanism,” Saudi Journal of Biological Sciences, vol. 27, no. 2, pp. 606–610, 2020.

[16] X. Zhang, S. Wang, G. Lin, and D. Wang, “Down-regulation of circ-PTN suppresses cell proliferation, invasion and glycolysis in glioma by regulating miR-432-5p/RAB10 axis,” Neuroscience Letters, vol. 735, article 135153, 2020.

[17] K. Peng, Y. Bai, Q. Zhu, B. Hu, and Y. Xu, “Targeting VEGF-neuropilin interactions: a promising antitumor strategy,” Drug Discovery Today, vol. 24, no. 2, pp. 656–664, 2019.

[18] N. Niesler, J. Arndt, K. Silberreis, and H. Fuchs, “Generation of a soluble and stable apoptin-EGF fusion protein, a targeted viral protein applicable for tumor therapy,” Protein Expression and Purification, vol. 175, article 105687, 2020.

[19] X. Liao, H. Li, Z. Liu et al., “Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment,” Medicine, vol. 97, no. 50, article e13635e, 2018.

[20] Y. Guo, J. Tang, X. E. Huang, and J. Cao, “Efficacy and toxicity of apatinib combined with or without chemotherapy for patients with advanced or metastatic chemotherapy-refractory gastric adenocarcinoma: a prospective clinical study,” Medicine, vol. 98, no. 6, article e13908, 2019.

[21] D. Zhang, C. Zhang, J. Huang, Y. Guan, and Q. Guo, “Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non-small cell lung cancer after second-line chemotherapy treatment: a retrospective study,” Thoracic Cancer, vol. 9, no. 12, pp. 1754–1762, 2018.